GlassScriptPhysician profile
Kyle Joseph Feldmann
NPI 1932465465
$19,857.09
in general payments reported to CMS, 2019-2025
28 companies · $9,585 in 2025
The $9,585 reported for 2025 was more than what 88% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $141 · 2021: $112 · 2022: $839 · 2023: $1,864 · 2024: $7,074 · 2025: $9,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $3,075 · Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,500.00 |
| Travel and Lodging | $3,075.09 |
| Food and Beverage | $2,948.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17,465.09 | 2022-2025 | General - Balloons, Avvigo Guidance System, Opticross |
| Shockwave Medical, INC | $363.36 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $285.58 | 2019-2025 | |
| Pfizer INC. | $180.03 | 2019-2025 | |
| Teleflex LLC | $174.14 | 2024 | Turnpike |
| Biotronik INC. | $150.00 | 2022 | |
| Abiomed | $148.73 | 2022 | |
| Abbott Laboratories | $118.75 | 2022-2024 | Diamondback Coronary, Pressurewire, Cardiomems |
| Jenavalve Technology, INC. | $112.14 | 2022 | |
| Medtronic, INC. | $105.54 | 2021-2024 | Corevalve Evolut R |
| Heartflow, INC. | $100.84 | 2025 | |
| Janssen Pharmaceuticals, INC | $99.39 | 2019-2022 | |
| Amgen INC. | $81.56 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $77.48 | 2020-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $62.34 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $61.58 | 2024-2025 | Kengreal, Cleviprex |
| Edwards Lifesciences Corporation | $30.31 | 2024-2025 | Sapien 3 Ultra Resilia |
| Cardiva Medical, INC. | $30.12 | 2025 | Cardiva Vascade 6/7f Vcs |
| Amarin Pharma, INC. | $28.73 | 2019 | |
| Cvrx, INC. | $25.81 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.61 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $22.97 | 2019-2020 | |
| Getinge USA Sales, LLC | $22.88 | 2022 | |
| Astellas Pharma US INC | $19.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2019 | |
| Medtronic Vascular, INC. | $16.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.26 | 2023-2024 | Lifevest |
| Cardiovascular Systems INC. | $13.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Feldmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.